NEW YORK — New Horizon Health said today that it has signed an agreement to commercialize its ColoClear colorectal cancer test in Hong Kong and certain other Asian markets with Prenetics.
According to New Horizon Health, which is based in Hangzhou, China, ColoClear is a stool-based DNA test specifically designed to detect colon cancer in individuals of Asian descent, with 92 percent sensitivity demonstrated in clinical studies.
Under the terms of the deal, New Horizon Health will transfer the technology underlying the ColoClear to Hong Kong-based Prenetics, which will establish a dedicated facility within its laboratory to commercialize the test. Prenetics is slated to launch the test in Hong Kong in early 2020 and in Southeast Asia later that year.
Additional terms were not disclosed.
"Colon cancer is one of the most common cancers in Hong Kong and in Southeast Asia," Prenetics CEO Danny Yeung said in a statement. "Through our initial market research, we have already received immensely positive responses from Insurers, clinics, hospitals, and consumers on ColoClear."
About a year ago, Prenetics partnered with Berry Genomics to introduce a range of direct-to-consumer genetic testing services to the Chinese market. Earlier in 2018, Prenetics acquired UK-based consumer genomics form DNAFit for $10 million.